‌

US Patent 12012462 Chimeric receptors to DLL3 and methods of use thereof

Patent 12012462 was granted and assigned to Amgen on June, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Michael John Giffin0

Ruben Alvarez Rodriguez0

Jun Feng0

Ryan B. Case0

Melissa Thomas0

Lawren Wu0

Christopher Murawsky0

Jed J. Wiltzius0

Date of Patent

June 18, 2024

0

Patent Application Number

170467310

Date Filed

April 10, 2019

0

Patent Citations

US Patent 8436183 Synthetic multimerizing agents

0

US Patent 8486693 Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods

0

US Patent 9024028 Methods and compositions for the synthesis of multimerizing agents

0

US Patent 10428142 Multipartite signaling proteins and uses thereof

0

US Patent 9944690 Methods for controlling T cell proliferation

0

US Patent 10934346 Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12

0

US Patent 6867041 Simultaneous stimulation and concentration of cells

0

US Patent 6905874 Simultaneous stimulation and concentration of cells

0

...

Patent Primary Examiner

0

Patent abstract

Antigen binding molecules, chimeric receptors, and engineered immune cells to DLL3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the DLL3 antigen binding molecules and engineered immune cells.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12012462 Chimeric receptors to DLL3 and methods of use thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.